Biomarkers in NSCLC

Welcome to the Biomarkers in NSCLC Resource Center! Here you will find updated information, education, and other resources from the field of non-small cell lung cancer. We're excited to provide this offering to you and your colleagues. Take a look around, and send us your feedback to editor@advancedpractitioner.com

Rasheda Persinger, NP-C, Medical Oncology Lead Nurse Practitioner, Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center at Sibley Memorial Hospital

Biomarkers in NSCLC Resource Center

Interview With Andrew Lerner, MD, on Biomarker Testing

CAP/IASLC/AMP Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors

ASCO Educational Book: Acquired Resistance to Targeted Therapies in Advanced Non–Small-Cell Lung Cancer: New Strategies and New Agents

Next-generation Sequencing-based Detection of EGFR, KRAS, BRAF, NRAS, PIK3CA, Her-2 and TP53 Mutations in Patients With Non-small Cell Lung Cancer

KRAS G12C Biomarker Testing & Analysis

Molecular Testing Strategies in Non-small Cell Lung Cancer: Optimizing the Diagnostic Journey

Nature Reviews Clinical Oncology

Selecting the Optimal Immunotherapy Regimen in Driver-Negative Metastatic NSCLC

Cancer Cytopathology

The Rapidly Evolving Landscape of Biomarker Testing in Non–Small Cell Lung Cancer

European Journal of Cancer

RAS as a Positive Predictive Biomarker: Focus on Lung and Colorectal Cancer Patients

Journal of Clinical Oncology

Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study

JCO Oncology Practice

Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non–Small-Cell Lung Cancer Harboring MET Exon 14 Skipping

Frontiers in Oncology

Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events—A Comprehensive Review

Critical Reviews in Oncology/Hematology

Molecular Testing and Targeted Therapy for Non-Small Cell Lung Cancer: Current Status and Perspectives

Cell Reports Medicine

The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer

The Oncologist

Navigating Diagnostic and Treatment Decisions in Non-Small Cell Lung Cancer: Expert Commentary on the Multidisciplinary Team Approach

The ASCO Post

Poziotinib in Previously Treated Patients With NSCLC and HER2 Exon 20 Insertion Mutations

Fast Facts #10: Protocols, Pathways, and Platforms for Testing